RU2007129779A - Новые соединения пиридина - Google Patents
Новые соединения пиридина Download PDFInfo
- Publication number
- RU2007129779A RU2007129779A RU2007129779/04A RU2007129779A RU2007129779A RU 2007129779 A RU2007129779 A RU 2007129779A RU 2007129779/04 A RU2007129779/04 A RU 2007129779/04A RU 2007129779 A RU2007129779 A RU 2007129779A RU 2007129779 A RU2007129779 A RU 2007129779A
- Authority
- RU
- Russia
- Prior art keywords
- heterocyclyl
- aryl
- amino
- cycloalkyl
- ethyl
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 161
- 125000003118 aryl group Chemical group 0.000 claims 151
- -1 arylC (O) Chemical group 0.000 claims 132
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 74
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 72
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 64
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims 58
- 229910052794 bromium Inorganic materials 0.000 claims 54
- 229910052801 chlorine Inorganic materials 0.000 claims 54
- 229910052731 fluorine Inorganic materials 0.000 claims 54
- 125000005843 halogen group Chemical group 0.000 claims 54
- 229910052740 iodine Inorganic materials 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 49
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 48
- 125000004430 oxygen atom Chemical group O* 0.000 claims 48
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 46
- 125000004414 alkyl thio group Chemical group 0.000 claims 45
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 42
- 235000001968 nicotinic acid Nutrition 0.000 claims 42
- 239000011664 nicotinic acid Substances 0.000 claims 42
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 34
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 32
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 32
- 229960001238 methylnicotinate Drugs 0.000 claims 32
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 31
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 27
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 26
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 23
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 23
- 125000005110 aryl thio group Chemical group 0.000 claims 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 23
- 125000004122 cyclic group Chemical group 0.000 claims 22
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 17
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 17
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 16
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 15
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 15
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 claims 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000005304 joining Methods 0.000 claims 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- UBLUZXPVNMESOL-UHFFFAOYSA-N ethyl 6-[3-(benzenesulfonylcarbamoylamino)azetidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(NC(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 UBLUZXPVNMESOL-UHFFFAOYSA-N 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- ACRKCTJODRGHSP-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)NC(=O)C1CCNCC1 ACRKCTJODRGHSP-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- YXGKOLAZDGNTBX-UHFFFAOYSA-N 1-[3-chloro-4-(dimethylamino)-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)N(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 YXGKOLAZDGNTBX-UHFFFAOYSA-N 0.000 claims 1
- KTGUJCHPSDTAKP-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-(methylamino)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)NC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 KTGUJCHPSDTAKP-UHFFFAOYSA-N 0.000 claims 1
- MXXJAGIMRLDJFK-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-6-(methylamino)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(Cl)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1NC MXXJAGIMRLDJFK-UHFFFAOYSA-N 0.000 claims 1
- OTNVITBUUXZTQF-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-6-methoxypyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(Cl)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1OC OTNVITBUUXZTQF-UHFFFAOYSA-N 0.000 claims 1
- LLNLUPUKRRVHGT-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylazetidine-3-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 LLNLUPUKRRVHGT-UHFFFAOYSA-N 0.000 claims 1
- RNEYONGXTVFBHV-UHFFFAOYSA-N 1-[4-amino-3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)N)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RNEYONGXTVFBHV-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- YPFCJBJMMACVBE-UHFFFAOYSA-N 3-[1-(benzenesulfonylcarbamoyl)-4-(3-chloro-5-ethoxycarbonylpyridin-2-yl)piperazin-2-yl]propanoic acid Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 YPFCJBJMMACVBE-UHFFFAOYSA-N 0.000 claims 1
- IUFLJCZIMLKGQN-UHFFFAOYSA-N 3-[1-(benzenesulfonylcarbamoyl)-4-[3-cyano-5-ethoxycarbonyl-6-(trifluoromethyl)pyridin-2-yl]piperazin-2-yl]propanoic acid Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 IUFLJCZIMLKGQN-UHFFFAOYSA-N 0.000 claims 1
- ICKIAJXQACGDGC-UHFFFAOYSA-N 3-[1-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-4-[3-cyano-5-[ethoxy(hydroxy)methyl]-6-(trifluoromethyl)pyridin-2-yl]piperazin-2-yl]propanoic acid Chemical compound N1=C(C(F)(F)F)C(C(O)OCC)=CC(C#N)=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 ICKIAJXQACGDGC-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- VGMHGUWPHMZGNB-UHFFFAOYSA-N 4-(5-butanoyl-3-chloropyridin-2-yl)-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound ClC1=CC(C(=O)CCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VGMHGUWPHMZGNB-UHFFFAOYSA-N 0.000 claims 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- QDGXKCGRYRQCFY-UHFFFAOYSA-N 4-[3-chloro-5-(2-ethyltetrazol-5-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound CCN1N=NC(C=2C=C(Cl)C(N3CCN(CC3)C(=O)NS(=O)(=O)C=3SC(Cl)=CC=3)=NC=2)=N1 QDGXKCGRYRQCFY-UHFFFAOYSA-N 0.000 claims 1
- VZAZKZSGKCDENO-UHFFFAOYSA-N 4-[3-chloro-5-(3-methyl-1,2-oxazol-5-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1N=C(C)C=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VZAZKZSGKCDENO-UHFFFAOYSA-N 0.000 claims 1
- UQGABJOTOYVCCV-UHFFFAOYSA-N 4-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 UQGABJOTOYVCCV-UHFFFAOYSA-N 0.000 claims 1
- JZUVWUCVDGUZFC-UHFFFAOYSA-N 4-[3-chloro-5-(5-methyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 JZUVWUCVDGUZFC-UHFFFAOYSA-N 0.000 claims 1
- VEJNOPYLXFLQPA-UHFFFAOYSA-N 4-[3-chloro-5-(cyclopropanecarbonyl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)NC(=O)N1CCN(C=2C(=CC(=CN=2)C(=O)C2CC2)Cl)CC1 VEJNOPYLXFLQPA-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- ZETANZUWYPHWDA-UHFFFAOYSA-N azetidine;pyrrolidine Chemical compound C1CNC1.C1CCNC1 ZETANZUWYPHWDA-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- RQEHXCUFAJNTHP-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RQEHXCUFAJNTHP-UHFFFAOYSA-N 0.000 claims 1
- TUEKMSMEFFRCRK-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[5-(1,2-oxazol-5-yl)thiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C=2ON=CC=2)C1 TUEKMSMEFFRCRK-UHFFFAOYSA-N 0.000 claims 1
- BGXQTUVWYLQULN-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dichlorothiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(SC(Cl)=C2)Cl)C1 BGXQTUVWYLQULN-UHFFFAOYSA-N 0.000 claims 1
- IDRBWZGCZZKPHJ-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dimethylfuran-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(OC(C)=C2)C)C1 IDRBWZGCZZKPHJ-UHFFFAOYSA-N 0.000 claims 1
- UTEGZDGSGWVSOL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dimethylthiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(SC(C)=C2)C)C1 UTEGZDGSGWVSOL-UHFFFAOYSA-N 0.000 claims 1
- JYYCHOJJACQKFL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4,5-dichlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=C(Cl)C=2)C1 JYYCHOJJACQKFL-UHFFFAOYSA-N 0.000 claims 1
- NJFDXLVTTSQPFC-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC3=CC(OCC)=CC=C3N=2)C1 NJFDXLVTTSQPFC-UHFFFAOYSA-N 0.000 claims 1
- AINYGOJLEKAPSB-UHFFFAOYSA-N ethyl 6-[3-(1-benzothiophen-3-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=CC=CC=C3SC=2)C1 AINYGOJLEKAPSB-UHFFFAOYSA-N 0.000 claims 1
- WJILKOXJPCLHAH-UHFFFAOYSA-N ethyl 6-[3-(2,1,3-benzothiadiazol-4-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=NSN=C3C=CC=2)C1 WJILKOXJPCLHAH-UHFFFAOYSA-N 0.000 claims 1
- RSGPBIDJRJPCAV-UHFFFAOYSA-N ethyl 6-[3-(2,1,3-benzoxadiazol-4-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=NON=C3C=CC=2)C1 RSGPBIDJRJPCAV-UHFFFAOYSA-N 0.000 claims 1
- QMUBZDPIKPJIAM-UHFFFAOYSA-N ethyl 6-[3-[(2-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)C1 QMUBZDPIKPJIAM-UHFFFAOYSA-N 0.000 claims 1
- YTYTVBHMGSRCRN-UHFFFAOYSA-N ethyl 6-[3-[(3-bromo-5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C=C(Cl)S2)Br)C1 YTYTVBHMGSRCRN-UHFFFAOYSA-N 0.000 claims 1
- BPLBHGMLIYZDHX-UHFFFAOYSA-N ethyl 6-[3-[(3-bromophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Br)C=CC=2)C1 BPLBHGMLIYZDHX-UHFFFAOYSA-N 0.000 claims 1
- UKLTWOHKSDYECL-UHFFFAOYSA-N ethyl 6-[3-[(3-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Cl)C=CC=2)C1 UKLTWOHKSDYECL-UHFFFAOYSA-N 0.000 claims 1
- PNUQKPNRDARCJX-UHFFFAOYSA-N ethyl 6-[3-[(4-bromo-5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=C(Br)C=2)C1 PNUQKPNRDARCJX-UHFFFAOYSA-N 0.000 claims 1
- XJAUTURGAVKIGW-UHFFFAOYSA-N ethyl 6-[3-[(4-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)C1 XJAUTURGAVKIGW-UHFFFAOYSA-N 0.000 claims 1
- XTRNTMPKWKEDFN-UHFFFAOYSA-N ethyl 6-[3-[(5-bromo-6-chloropyridin-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Br)C(Cl)=NC=2)C1 XTRNTMPKWKEDFN-UHFFFAOYSA-N 0.000 claims 1
- VKIAIPSYXFDGAT-UHFFFAOYSA-N ethyl 6-[3-[(5-bromothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Br)=CC=2)C1 VKIAIPSYXFDGAT-UHFFFAOYSA-N 0.000 claims 1
- MFBHEUSXFARQEY-UHFFFAOYSA-N ethyl 6-[3-[(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(N(C)N=C2C)Cl)C1 MFBHEUSXFARQEY-UHFFFAOYSA-N 0.000 claims 1
- NLKBKVGXCVMBPS-UHFFFAOYSA-N ethyl 6-[3-[(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)C1 NLKBKVGXCVMBPS-UHFFFAOYSA-N 0.000 claims 1
- IQELNXOCRWDSJQ-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-3-methylazetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C)(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 IQELNXOCRWDSJQ-UHFFFAOYSA-N 0.000 claims 1
- DXRGSOKOVRDWNW-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 DXRGSOKOVRDWNW-UHFFFAOYSA-N 0.000 claims 1
- CILSRBUAKHLULT-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Cl)SC=2)C1 CILSRBUAKHLULT-UHFFFAOYSA-N 0.000 claims 1
- BTIAERCPSGMCCD-UHFFFAOYSA-N ethyl 6-[3-[2-(benzenesulfonamido)-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2C=CC=CC=2)CCC1 BTIAERCPSGMCCD-UHFFFAOYSA-N 0.000 claims 1
- LBVFFPZDCSCYIN-UHFFFAOYSA-N ethyl 6-[3-[2-[(5-chlorothiophen-2-yl)sulfonylamino]-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CCC1 LBVFFPZDCSCYIN-UHFFFAOYSA-N 0.000 claims 1
- OLFOOGHYEKTXRY-UHFFFAOYSA-N ethyl 6-[3-[[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]methyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CNC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 OLFOOGHYEKTXRY-UHFFFAOYSA-N 0.000 claims 1
- FWXUMSNWEZCCIT-UHFFFAOYSA-N ethyl 6-[3-[[4-(4-chlorophenyl)sulfonyl-3-methylthiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C(=CS2)S(=O)(=O)C=2C=CC(Cl)=CC=2)C)C1 FWXUMSNWEZCCIT-UHFFFAOYSA-N 0.000 claims 1
- MSQMWODDPRBPJG-UHFFFAOYSA-N ethyl 6-[4-(2,1,3-benzoxadiazol-4-ylsulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C3=NON=C3C=CC=2)CC1 MSQMWODDPRBPJG-UHFFFAOYSA-N 0.000 claims 1
- SLFSAOTXKZLYMH-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-1,4-diazepan-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CCC1 SLFSAOTXKZLYMH-UHFFFAOYSA-N 0.000 claims 1
- KRICGQWFOCXJGJ-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(CCC(=O)OC(C)(C)C)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 KRICGQWFOCXJGJ-UHFFFAOYSA-N 0.000 claims 1
- XAQZFANMDXCKCF-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(=O)OC(C)(C)C)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 XAQZFANMDXCKCF-UHFFFAOYSA-N 0.000 claims 1
- PHZXEFQHQGATEP-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperazin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 PHZXEFQHQGATEP-UHFFFAOYSA-N 0.000 claims 1
- HZWVJSZPVJHIRF-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 HZWVJSZPVJHIRF-UHFFFAOYSA-N 0.000 claims 1
- QRBKIMPLBWIGHP-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 QRBKIMPLBWIGHP-UHFFFAOYSA-N 0.000 claims 1
- RBEPZLOCUMMCFC-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoylamino)piperidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(NC(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 RBEPZLOCUMMCFC-UHFFFAOYSA-N 0.000 claims 1
- MWNQODBRDGOPEN-UHFFFAOYSA-N ethyl 6-[4-[(2-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)CC1 MWNQODBRDGOPEN-UHFFFAOYSA-N 0.000 claims 1
- QPTUDBWQWSMCEA-UHFFFAOYSA-N ethyl 6-[4-[(4-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 QPTUDBWQWSMCEA-UHFFFAOYSA-N 0.000 claims 1
- WXFHJUTYLPESPH-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-1,4-diazepan-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CCC1 WXFHJUTYLPESPH-UHFFFAOYSA-N 0.000 claims 1
- CSJGQSBCSQFHSP-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-2-methylpiperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1C(C)CN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CSJGQSBCSQFHSP-UHFFFAOYSA-N 0.000 claims 1
- RGQQNQKBNSJCLB-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-4-methylpiperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C)(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RGQQNQKBNSJCLB-UHFFFAOYSA-N 0.000 claims 1
- VHZYXGNZMRAFNP-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VHZYXGNZMRAFNP-UHFFFAOYSA-N 0.000 claims 1
- CMEULPCPRSODMC-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-2,4-dimethylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=C(C)C=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CMEULPCPRSODMC-UHFFFAOYSA-N 0.000 claims 1
- CFTMMJHRAWMXEM-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-ethylpyridine-3-carboxylate Chemical compound N1=C(CC)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CFTMMJHRAWMXEM-UHFFFAOYSA-N 0.000 claims 1
- YVEPQWPFZNTAAE-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 YVEPQWPFZNTAAE-UHFFFAOYSA-N 0.000 claims 1
- PCCHEJANPILTFZ-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-phenylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C1=CC=CC=C1 PCCHEJANPILTFZ-UHFFFAOYSA-N 0.000 claims 1
- XPUHLVFTFLMVKI-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-propan-2-ylpyridine-3-carboxylate Chemical compound N1=C(C(C)C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XPUHLVFTFLMVKI-UHFFFAOYSA-N 0.000 claims 1
- GFVMYYVRTZJDHI-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 GFVMYYVRTZJDHI-UHFFFAOYSA-N 0.000 claims 1
- FLCWYHVLJNVKMZ-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-3-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(Cl)SC=2)CC1 FLCWYHVLJNVKMZ-UHFFFAOYSA-N 0.000 claims 1
- NWSAQANIQYQTHL-UHFFFAOYSA-N ethyl 6-[4-[2-(benzenesulfonamido)-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(CC(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 NWSAQANIQYQTHL-UHFFFAOYSA-N 0.000 claims 1
- ORDYIRKFBRMZAQ-UHFFFAOYSA-N ethyl 6-[4-[2-[(5-chlorothiophen-2-yl)sulfonylamino]-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(CC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 ORDYIRKFBRMZAQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- ALMLISXWGBQUKI-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C ALMLISXWGBQUKI-UHFFFAOYSA-N 0.000 claims 1
- OKVOIJXNIGRZNY-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 OKVOIJXNIGRZNY-UHFFFAOYSA-N 0.000 claims 1
- UACQSHPMVFGLEW-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-ethyl-4,5-dihydro-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(CC)CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 UACQSHPMVFGLEW-UHFFFAOYSA-N 0.000 claims 1
- GMHMCXJIVCUHHK-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-methyl-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 GMHMCXJIVCUHHK-UHFFFAOYSA-N 0.000 claims 1
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 claims 1
- JTNZXLLKKARAHG-UHFFFAOYSA-N tert-butyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C1=C(C(=O)OC(C)(C)C)C(C)=NC(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)=C1C#N JTNZXLLKKARAHG-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *C(c1cc(*)c(N2CC3C=CC(*C(NS(*)(=O)=O)=O)CC3C2)nc1*)=O Chemical compound *C(c1cc(*)c(N2CC3C=CC(*C(NS(*)(=O)=O)=O)CC3C2)nc1*)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500140A GB0500140D0 (en) | 2005-01-06 | 2005-01-06 | Novel compounds |
| GB0500140.9 | 2005-01-06 | ||
| GB0521484A GB0521484D0 (en) | 2005-10-21 | 2005-10-21 | Novel compounds |
| GB0521484.6 | 2005-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007129779A true RU2007129779A (ru) | 2009-02-20 |
Family
ID=36647772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007129779/04A RU2007129779A (ru) | 2005-01-06 | 2006-01-04 | Новые соединения пиридина |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090227555A2 (enExample) |
| EP (1) | EP1836189A1 (enExample) |
| JP (1) | JP2008526840A (enExample) |
| KR (1) | KR20070107024A (enExample) |
| AR (1) | AR055554A1 (enExample) |
| AU (1) | AU2006204159A1 (enExample) |
| BR (1) | BRPI0606437A (enExample) |
| CA (1) | CA2594255A1 (enExample) |
| IL (1) | IL183961A0 (enExample) |
| MX (1) | MX2007008237A (enExample) |
| NO (1) | NO20073101L (enExample) |
| RU (1) | RU2007129779A (enExample) |
| TW (1) | TW200626593A (enExample) |
| UY (1) | UY29325A1 (enExample) |
| WO (1) | WO2006073361A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312208A1 (en) * | 2005-07-13 | 2008-12-18 | Astrazeneca Ab | Pyridine Analogues |
| WO2008004941A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| WO2008004945A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline forms i and ii |
| TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| WO2008004944A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline form ii |
| UY30867A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos analogos de piridina vii 543 |
| UY30868A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones. |
| UY30866A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolos y aplicaciones (519) |
| MX2009013431A (es) * | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| US20090018166A1 (en) * | 2007-07-13 | 2009-01-15 | Astrazeneca Ab | New Pyridine Analogues X 161 |
| WO2010005385A1 (en) * | 2008-07-07 | 2010-01-14 | Astrazeneca Ab | 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308 |
| WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP2014051434A (ja) * | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| SG11201500900YA (en) | 2012-08-21 | 2015-03-30 | Hoffmann La Roche | Novel pyridine derivatives |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| KR20240057402A (ko) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 그람 음성 박테리아 유출 펌프 억제제 |
| AU2023388768A1 (en) | 2022-12-06 | 2025-05-01 | Idorsia Pharmaceuticals Ltd | Crystalline adipic acid salt form of a ccr6 antagonist |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3133073B2 (ja) * | 1995-05-29 | 2001-02-05 | ファイザー・インコーポレーテッド | 成長ホルモンの放出を促進するジペプチド類 |
| EP1009405A4 (en) * | 1997-08-28 | 2001-05-09 | Merck & Co Inc | PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| FR2820057A1 (fr) * | 2001-01-30 | 2002-08-02 | Ct De Transfert De Technologie | Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane |
| WO2003022214A2 (en) * | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) * | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| WO2006012226A2 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| AU2007270083A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| WO2008004941A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
-
2006
- 2006-01-04 WO PCT/SE2006/000010 patent/WO2006073361A1/en not_active Ceased
- 2006-01-04 CA CA002594255A patent/CA2594255A1/en not_active Abandoned
- 2006-01-04 BR BRPI0606437-0A patent/BRPI0606437A/pt not_active IP Right Cessation
- 2006-01-04 MX MX2007008237A patent/MX2007008237A/es not_active Application Discontinuation
- 2006-01-04 JP JP2007550328A patent/JP2008526840A/ja active Pending
- 2006-01-04 AU AU2006204159A patent/AU2006204159A1/en not_active Abandoned
- 2006-01-04 EP EP06700210A patent/EP1836189A1/en not_active Withdrawn
- 2006-01-04 RU RU2007129779/04A patent/RU2007129779A/ru not_active Application Discontinuation
- 2006-01-04 US US11/813,289 patent/US20090227555A2/en not_active Abandoned
- 2006-01-04 KR KR1020077018077A patent/KR20070107024A/ko not_active Withdrawn
- 2006-01-05 UY UY29325A patent/UY29325A1/es unknown
- 2006-01-05 AR ARP060100040A patent/AR055554A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100677A patent/TW200626593A/zh unknown
-
2007
- 2007-06-14 IL IL183961A patent/IL183961A0/en unknown
- 2007-06-18 NO NO20073101A patent/NO20073101L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042852A1 (en) | 2009-02-12 |
| AR055554A1 (es) | 2007-08-22 |
| JP2008526840A (ja) | 2008-07-24 |
| IL183961A0 (en) | 2007-10-31 |
| TW200626593A (en) | 2006-08-01 |
| CA2594255A1 (en) | 2006-07-13 |
| MX2007008237A (es) | 2007-08-17 |
| BRPI0606437A (pt) | 2008-03-11 |
| UY29325A1 (es) | 2006-08-31 |
| NO20073101L (no) | 2007-07-19 |
| WO2006073361A9 (en) | 2007-08-02 |
| AU2006204159A1 (en) | 2006-07-13 |
| KR20070107024A (ko) | 2007-11-06 |
| EP1836189A1 (en) | 2007-09-26 |
| WO2006073361A1 (en) | 2006-07-13 |
| US20090227555A2 (en) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526840A5 (enExample) | ||
| JP2006500348A5 (enExample) | ||
| RU2006129492A (ru) | Производные индола и их применение в качестве ингибиторов киназ, в частности, ингибиторов ikk2 | |
| RU2454415C9 (ru) | Производное индола | |
| RU2491285C2 (ru) | Органические соединения | |
| CA2396824A1 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| JP2007531752A5 (enExample) | ||
| JP2006516145A5 (enExample) | ||
| JP2012526803A5 (enExample) | ||
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| JP2006500369A5 (enExample) | ||
| JP2009510170A5 (enExample) | ||
| SK284675B6 (sk) | Derivát acylpiperazinylpyrimidínu, spôsob jeho prípravy a farmaceutická kompozícia na jeho báze | |
| RU2011115111A (ru) | Замещенные пирролидин-2-карбоксамиды | |
| JP2022553832A5 (enExample) | ||
| JP2010513304A5 (enExample) | ||
| JP2007519735A5 (enExample) | ||
| HUE031580T2 (en) | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents | |
| CA2550596A1 (en) | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | |
| RU2007107349A (ru) | Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств | |
| RU2007120519A (ru) | Арилоксизамещенное производное бензимидазола | |
| EA026361B1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| JP2020500192A5 (enExample) | ||
| RU2019117958A (ru) | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 | |
| WO2006073361A1 (en) | Novel pyridine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100304 |